• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.

作者信息

Bouguen Guillaume, Siproudhis Laurent

机构信息

Hopital Pontchaillou, Service des Maladies de l'Appareil Digestif, Rennes Cedex, France.

出版信息

Aliment Pharmacol Ther. 2019 Mar;49(6):817-818. doi: 10.1111/apt.15151.

DOI:10.1111/apt.15151
PMID:30811643
Abstract
摘要

相似文献

1
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.社论：使用治疗药物监测策略降低炎症性肠病患者英夫利昔单抗剂量——初现希望但仍需更多数据。作者回复
Aliment Pharmacol Ther. 2019 Mar;49(6):817-818. doi: 10.1111/apt.15151.
2
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
Aliment Pharmacol Ther. 2019 Mar;49(6):816-817. doi: 10.1111/apt.15081.
3
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.治疗药物监测可预测临床缓解的炎症性肠病患者英夫利昔单抗治疗降阶梯后反应丧失的情况。
Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.
4
Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?抗TNF-α治疗药物监测对于考虑降低治疗强度是否有用？
Expert Opin Biol Ther. 2015;15(11):1657-60. doi: 10.1517/14712598.2015.1069273. Epub 2015 Jul 20.
5
Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
Aliment Pharmacol Ther. 2017 May;45(10):1372. doi: 10.1111/apt.14060.
6
Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.
Aliment Pharmacol Ther. 2018 Sep;48(5):578-579. doi: 10.1111/apt.14907.
7
Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.
Aliment Pharmacol Ther. 2018 Feb;47(3):436-437. doi: 10.1111/apt.14461.
8
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.在活动性炎症性肠病中，与仅依靠临床决策相比，通过治疗药物监测来指导英夫利昔单抗剂量调整与更好的内镜检查结果相关。
Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209. doi: 10.1097/MIB.0000000000001126.
9
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply.社论：炎症性肠病中对CT-P13和英夫利昔单抗原研药的抗原反应显示相似的表位识别——来自基础科学的证据支持安全转换为生物类似药。作者回复。
Aliment Pharmacol Ther. 2018 Sep;48(5):575-576. doi: 10.1111/apt.14860.
10
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.英夫利昔单抗治疗药物监测在炎症性肠病的虚拟生物制剂临床中改变了临床决策。
Inflamm Bowel Dis. 2017 Dec;23(12):2083-2088. doi: 10.1097/MIB.0000000000001258.